timothy sykes logo
Celcuity’s Stock Soars with Promising Phase 3 Results Thumbnail
ADD US ONG Google News

Celcuity’s Stock Soars with Promising Phase 3 Results

TIM SYKES•UPDATED NOV. 14, 2025, 4:09 PM ET
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

Celcuity Inc.’s stocks have been trading up by 8.23 percent following promising developments and heightened investor optimism.

Healthcare industry expert:

Analyst sentiment – positive

Celcuity Inc. (CELC), with a significant enterprise value of $3.5 billion, faces notable financial challenges. Its metrics indicate a precarious market position, evidenced by a price-to-book ratio of 81.41 and a highly negative return on equity of -134.54%. The company’s operations reveal substantial losses, with an EBITDA of -$38.39 million, displaying unsustainable financial management. Despite these metrics, a robust current ratio of 4.6 suggests liquidity remains adequate short-term. However, the long-term outlook, disrupted by a -$44.69 return on assets, raises critical sustainability concerns, indicating a potential need for strategic realignment.

Technically, Celcuity’s weekly price patterns showcase a bullish trend, escalating from $76.7 to $92.68. This upward momentum, driven by significant volume spikes, indicates strong investor confidence—pushed by recent positive clinical outcomes. The 5-minute candle analysis highlights consistent buying pressure, maintaining levels above the key support of $85. For traders, buying on pullbacks near $86 could prove profitable, with potential advancement to test resistance at $95. Given the sustained upward trajectory reinforced by technical indicators, a “buy-the-dip” approach is advisable, maintaining vigilance on volume analytics for momentum confirmation.

Catalysts such as the successful Phase 3 trial results for gedatolisib have fueled Celcuity’s stock surge beyond Healthcare and Biotechnology benchmarks. Analyst upgrades by Stifel and Craig-Hallum, with price targets ranging from $95 to $115, mirror the company’s robust potential in oncology treatment advancements. This optimism, coupled with a stronger-than-expected Q3 EPS, strengthens the outlook for sustained performance increases. Immediate resistance is foreseen around $95, mirroring analyst forecasts, with support firmly supporting the stock at $76. My sentiment remains significantly positive, predicated on ongoing market enthusiasm and substantial clinical milestones achieved.

Candlestick Chart

Weekly Update Nov 10 – Nov 14, 2025: On Friday, November 14, 2025 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 8.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Celcuity’s recent financial reports demonstrate a challenging fiscal year, but the firm has successfully navigated key market adversities. Despite a reported adjusted loss per share being higher at $0.78 compared to the previous year, it has surpassed analyst projections of a loss of $0.96. The company’s robust funding extends through 2027, providing a stable runway for future operations and innovations.

The liquidity ratios indicate a healthy financial stance with a current ratio of 4.6, an encouraging sign for meeting short-term obligations. However, profitability remains under stress as indicated by negative margins and earnings ratios, with a pretax profit showing a deficit in both annual and latest quarterly reports.

A closer look at their recent stock performance reveals a marked increase, with the stock price climbing sharply from an October 13 close of $86.20 to as high as $92.68 on November 14. Heightened volatility suggests an optimistic market response to potentially groundbreaking clinical advancements. Additionally, the market capitalization mirrors the upward momentum with an enterprise value now standing at approximately $3.51 billion.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading CELC

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”